- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.07. | Novo, Alvotech face continued FDA scrutiny at plants tied to recent FDA rejections | 21 | FiercePharma | ||
| ALVOTECH SDR Aktie jetzt für 0€ handeln | |||||
| 03.07. | Alvotech: Transactions of Managers and Closely Associated Persons | 8 | GlobeNewswire (USA) | ||
| 02.07. | Alvotech S.A. - Increase in share capital | 320 | GlobeNewswire | With reference to an announcement published by Alvotech S.A. (symbol: ALVO) on June 18, 2026, the total nominal value of the company's listed share capital on Nasdaq Iceland hf. will be increased... ► Artikel lesen | |
| 01.07. | Alvotech - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| 01.07. | Biotech firm Alvotech expands capital access with $75M term loan facility | 10 | Seeking Alpha | ||
| 01.07. | Alvotech further strengthens liquidity by securing term loan facility of $75 million | 483 | GlobeNewswire (Europe) | $75 million additional term loan facility maturing December 31, 2027, led by GoldenTree Asset ManagementFollows recent $165m equity raise strengthening cash positionIncluding equity financing and... ► Artikel lesen | |
| 23.06. | Alvotech: Transactions of Managers and Closely Associated Persons | 13 | GlobeNewswire (USA) | ||
| 20.06. | Alvotech (ALVO): 10 Penny Stocks With Explosive Growth Potential | 9 | Insider Monkey | ||
| 18.06. | Amended: Alvotech Announces $125 Mln Public Offering, Concurrent Private Placement | 19 | RTTNews | ||
| 18.06. | Alvotech Announces IPO Of Shares And Concurrent Private Placement. Expects To Get $125 Mln | 657 | AFX News | REYKJAVIK (dpa-AFX) - Alvotech announces $125 mln IPO, Concurrent Private PlacementOn Thursday, Alvotech (ALVO), a biotechnology company based in Iceland, announced the commencement of the underwritten... ► Artikel lesen | |
| 18.06. | Alvotech closes $98M public offering at $3.75 per share | 14 | Investing.com | ||
| 18.06. | Alvotech launches public offering targeting $125 million | 4 | Investing.com | ||
| 18.06. | Alvotech kündigt öffentliches Angebot über 125 Millionen US-Dollar an | 3 | Investing.com Deutsch | ||
| 18.06. | Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement | 658 | GlobeNewswire (Europe) | REYKJAVIK, ICELAND (June 18, 2026) - Alvotech (NASDAQ: ALVO; ALVO-SDB) ("Alvotech" or the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines... ► Artikel lesen | |
| 16.06. | Alvotech prices $85M stock offering, plans additional raise via private placement | 20 | Seeking Alpha | ||
| 16.06. | Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement | 13 | GlobeNewswire (USA) | ||
| 15.06. | Alvotech initiates $125M fundraising via public and private offering for biosimilar growth | 8 | Seeking Alpha | ||
| 15.06. | Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares | 12 | GlobeNewswire (USA) | ||
| 15.06. | Alvotech - 6-K, Report of foreign issuer | 9 | SEC Filings | ||
| 10.06. | Alvotech: Transactions of Managers and Closely Associated Persons | 12 | GlobeNewswire (USA) |
1 2 3 4 5 Weiter >>
85 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| LINEAGE CELL THERAPEUTICS | 0,937 | +2,97 % | Regenerative Medizin im Aufbruch: NurExone Biologic, Regenxbio und Lineage Cell Therapeutics setzen auf unterschiedliche Zukunftstechnologien | ||
| NOVOGENIA | 6,250 | -3,10 % | Novogenia baut neuen Standort in Hallwang | Die Novogenia AG hat mit dem Spatenstich den Bau ihrer neuen Firmenzentrale im österreichischen Hallwang begonnen. Auf mehr als 9.300 Quadratmetern entstehen dort Laborflächen, Produktionskapazitäten... ► Artikel lesen | |
| LYTIX BIOPHARMA | 0,792 | -1,74 % | LYTIX BIOPHARMA ASA: Lytix Biopharma Reports Phase II Data in Melanoma and Triple-Negative Breast Cancer for Ruxotemitide (LTX-315) in Combination with Pembrolizumab | ||
| CG ONCOLOGY | 73,52 | 0,00 % | CG Oncology bladder cancer trial results published in Lancet | ||
| RELAY THERAPEUTICS | 18,640 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| DYNE THERAPEUTICS | 25,630 | 0,00 % | Dyne Therapeutics Announces Pricing Of Upsized $375 Million Public Offering | ||
| KYMERA THERAPEUTICS | 110,05 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer | Dr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy across Kymera's industry-leading oral immunology portfolio Jared Gollob, MD, will retire from his... ► Artikel lesen | |
| TANGO THERAPEUTICS | 26,720 | 0,00 % | How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48% | ||
| VERA THERAPEUTICS | 35,180 | 0,00 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 52,74 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 60,12 | 0,00 % | Guggenheim cuts Tarsus Pharmaceuticals stock price target to $89 | ||
| ZENAS BIOPHARMA | 32,820 | 0,00 % | Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD | - BLA submission based on positive results from Phase 3 INDIGO trial - WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas," "Zenas BioPharma" or the "Company") (Nasdaq:... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 36,010 | 0,00 % | Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026 | ||
| APOGEE THERAPEUTICS | 134,31 | 0,00 % | Apogee Therapeutics Aktie erreicht Rekordhoch von 134,34 USD | ||
| PRAXIS PRECISION MEDICINES | 316,02 | +0,07 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen |
Das Unternehmen ALVOTECH SDR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 2,765 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALVOTECH SDR finden Sie auf Wallstreet Online.